Viloxazine: A Nonstimulant Treatment Option for ADHD
Researchers compare viloxazine as a nonstimulant treatment option to atomoxetine for managing inattention, hyperactivity, and impulsivity in pediatric and adult patients with ADHD.
Researchers compare viloxazine as a nonstimulant treatment option to atomoxetine for managing inattention, hyperactivity, and impulsivity in pediatric and adult patients with ADHD.
Researchers evaluated the benefits of a multimodal 12-week “brain fitness program” for individuals with ADHD, concussion, and memory loss.
Researchers sought to estimate the percentage of tic disorders in childhood that continued into adulthood, as well as the risk factors associated with tic disorder persistence.
Researchers from Sweden compared the height of men with and without ADHD before and after ADHD medication availability.
Health care providers are being advised to counsel patients not to share their medications.
Investigators surveyed adolescents and young adults with self-reported ADHD to determine what proportion already engage in tolerance breaks from their medication, and how often.
Investigators assessed the impact of age at initiation of prescription stimulant medication and duration of stimulant therapy in adolescents with ADHD on rates of misuse of prescription stimulants, methamphetamine, or cocaine.
This study was designed to be a current snapshot of the prevalence of and trends in mental disorders among children aged 9 to 10 years in the US.
This study looked at whether youth with ADHD following 24-HMB recommendations were less likely to have difficulty concentrating, remembering, or making decisions and making or keeping friends.
In October 2022, the US Food and Drug Administration announced a shortage of the immediate release formulation of amphetamine mixed salts.